Funding & VC

Neurotech Startup Science Lands $400M in Week of Nine Megadeals

Science's $400M Series D led U.S. megadeals, while London's Isomorphic Labs raised $5B. Nine U.S. startups landed $93M or more across neurotech, biotech and AI.

By Grace Kim

4 min read

The Week’s 10 Biggest Funding Rounds: $400M For Neurotech Leads, Followed By Big Deals For AI, Fintech, Biotech And More
The Week’s 10 Biggest Funding Rounds: $400M For Neurotech Leads, Followed By Big Deals For AI, Fintech, Biotech And MoreDarkoStojanovic / pixabay

What's News

  • Science raised a $400M Series D, bringing total funding past $900M.
  • Isomorphic Labs secured $5B in Series C funding led by Greenoaks and Sequoia Capital.
  • Model ML closed a $250M Series B at a $1.5B valuation led by General Atlantic and QED Investors.
  • Seven U.S. companies raised $100M or more in the week.
  • Anthropic completed its massive IPO while tech stocks dove sharply.

Brain-computer interface startup Science closed a $400 million Series D this week, the largest U.S. venture round announced and one of nine American deals at $93 million or more.

The round lifts total funding for the Alameda, California-based company past $900 million, according to Crunchbase's weekly megadeals tally. Science works on neural engineering and brain-computer interface technology, a field where capital keeps flowing despite a rough stretch for tech stocks.

That market backdrop matters. Tech equities took a sharp dive in recent days, and Anthropic pulled off its massive IPO in the same window — a big week for exits, but a volatile one. Crunchbase's analysts flag the obvious risk: if the negative sentiment and downward pressure persist, expect it to spill over into private markets.

For now, though, the money kept moving. Seven more U.S. companies announced rounds of $100 million or more. Here's the full board.

The ten biggest U.S. rounds

  • Science, $400M, neurotech. The Series D brings the Alameda, California company to more than $900 million raised to date.
  • Model ML, $250M, AI and fintech. The AI platform for financial and professional services closed a Series B at a $1.5 billion valuation. General Atlantic and QED Investors led the round. The company is three years old and operates from New York and London.
  • Galvanize Therapeutics, $130M, biotech. The Redwood City, California developer of pulsed electric field ablation technologies for oncology and chronic disease raised a Series D led by HealthQuest Capital.
  • General Flash, $128M, critical metals. The startup, which is developing a new method to produce critical metals, raised the money across seed and Series A rounds from a long list of investors.
  • Ramon.Space, $124M, space tech. The Denver-based developer of space computing infrastructure pulled in a Series B led by PSG.
  • Marrow Therapeutics, $120M, biotech. The Watertown, Massachusetts company launched with a combined $173 million in Series A and B funding. Orbimed led the $120 million Series B; Scion Life Sciences and venBio led the $53 million Series A. The startup develops bone marrow-targeted therapies for severe blood disorders.
  • Noeri, $110M, enterprise AI. The developer of self-improving AI for enterprises and researchers launched with $110 million in initial funding led by Menlo Ventures. The Palo Alto startup was founded by Stanford University computer science professors.
  • Seawolf Therapeutics, $100M, biotech. The San Diego startup emerged from stealth with $100 million raised to date for its novel DNA delivery platform. Versant Ventures, MPM BioImpact and Novartis Venture Fund served as lead investors.
  • BrightAI, $97M, physical AI. The Silicon Valley company secured $97 million in new funding led by Smith Point Capital. It builds a sensor, drone and robotics-driven platform for continuous observability in power, water and energy infrastructure.
  • Vincue, $93M, vehicle intelligence. The Kansas City developer of a vehicle lifecycle intelligence platform closed $93 million in growth capital led by Wavecrest Growth Partners.

Biotech claims three of the ten slots — four if you count the physical-AI-adjacent plays. The takeaway: life sciences and AI infrastructure absorbed most of the week's large checks.

What happened overseas?

The week's single largest financing actually landed in London. Isomorphic Labs, the UK-based startup applying AI to drug discovery, secured $5 billion in Series C funding — roughly twelve times the top U.S. round.

Greenoaks and Sequoia Capital led the financing for the five-year-old company, which also keeps offices in Massachusetts and Switzerland.

That deal alone dwarfs the combined U.S. top ten, which adds up to just over $1.4 billion. The plain read: global capital still has an enormous appetite for AI-plus-biotech, and it's willing to write the biggest checks outside U.S. borders to get it.

What does the week signal for private markets?

Two forces are pulling in opposite directions. On one side, public tech stocks just took a huge dive, and Crunchbase warns that sustained downward pressure would spill into private funding. On the other, this week's board shows nine-figure checks still clearing across neurotech, biotech, space, metals and enterprise AI.

Anthropic's IPO delivered the exit story of the week, and the megadeal pipeline stayed full. Whether both trends hold depends on how long the public-market slide runs — and history says private valuations rarely dodge that contagion forever.

Original: crunchbase.com

Share this article:

More from Grace Kim

Grace Kim

Show full bio

Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.

2,582 articles

Related articles

« Previous article